Upperton Pharma Solutions is a specialist CDMO (contract development and manufacturing organisation) providing formulation and dosage form development and clinical trial manufacturing services to the biotechnology and pharmaceutical industries. We offer our clients a complete development service, from early feasibility studies to process optimisation, scale up and clinical trial (GMP / IMP) manufacturing. We can enhance the performance and delivery of our client’s products by utilising an extensive range of formulation technologies. In particular, we have world-leading expertise and know-how in pharmaceutical spray dryings, probably the most versatile and fastest-growing technology in the industry. We have experience working with a range of dosage forms and the expertise to develop the most challenging of molecules. Our formulation work is supported by a comprehensive range of analytical services for product testing and ICH stability studies. Upperton has an extensive, multinational client base, ranging from virtual and small start-ups to global pharma companies. We pride ourselves on our client-focused, flexible approach and scientific excellence.
Looking for a particular Upperton Pharma Solutions employee's phone or email?
The Upperton Pharma Solutions annual revenue was $40.8 million in 2026.
Nikki Whitfield is the CEO of Upperton Pharma Solutions.
90 people are employed at Upperton Pharma Solutions.
Upperton Pharma Solutions is based in Beeston, England.
The NAICS codes for Upperton Pharma Solutions are [3254, 325, 32541, 32].
The SIC codes for Upperton Pharma Solutions are [283, 28].